Research on Scancell Holdings Plc (SCLP:LON)  from Trinity Delta

Trinity Delta view: iSCIB1+ currently represents c 50% of our Scancell company valuation and is a key value driver in our rNPV model with the next step change on first patient enrolment into the Phase III trial. The start of this study would trigger an uplift from our current 30% success probability to a still conservative 50% probability. This would raise our £407.5m ($530m) Scancell valuation to £548m ($712m). Nevertheless, the business and clinical update is a useful reminder there is more to Scancell than the ImmunoBody platform alone.

View Full Research